SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gibraltar Industries (ROCK) Reports Next Week: Wall Street Expects Earnings Growth

Gibraltar Industries (ROCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gibraltar to Announce Third Quarter 2026 Financial Results on November 5

Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the residential, agtech and infrastructure markets, announced today that it expects to release its third quarter 2026 financial results at approximately 7:30 a.m. ET on Thursday, November 5...

Gibraltar Industries (ROCK) Moves 7.0% Higher: Will This Strength Last?

Gibraltar Industries (ROCK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Everus Stock Falls 15% in Three Months: Is a Rebound Ahead?

ECG's shares slide 15.5% in three months, yet a record $4.55B backlog, cash flow and acquisitions stoke rebound hopes amid margin and valuation risks.

Gibraltar Industries Strikes $208 Million Deal to Sell Infrastructure Business, Cut Debt

Gibraltar Industries (ROCK) stock rose premarket after agreeing to sell its D.S. Brown unit to Saint-Gobain for $208 million.read more...

Gibraltar to Sell Infrastructure Business to Saint-Gobain for $208 Million

Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the residential and agtech markets, today announced that it has entered into an agreement to sell its Infrastructure business, D.S. Brown, to Saint-Gobain for $208 million in cash, subject to...

Transcript: Gibraltar Industries Q2 2026 Earnings Conference Call

Gibraltar Industries (NASDAQ:ROCK) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below.
Benzinga APIs provide real-time access to earnings callread more...

Zacks.com featured highlights include Banco Macro, Centene, Enersys, Gibraltar Industries and Kennametal

BMA, CNC, ENS, ROCK and KMT stand out among 18 stocks screened for low P/B ratios, attractive value and strong growth potential.

5 Low P/B Stocks With Attractive Value and Strong Growth Potential

BMA, CNC, ENS, ROCK and KMT stand out among low P/B stocks, with strong Value Scores and projected 3-5-year EPS growth of up to 32.4%.

ROCK or AGX: Which Is the Better Value Stock Right Now?

ROCK vs. AGX: Which Stock Is the Better Value Option?

Gibraltar Industries, Inc. engages in the manufacture and provision of products and services for the renewable energy, residential, and infrastructure markets. It operates through the following segments: Residential, Infrastructure, and Agtech. The Residential segment includes roof and foundation ventilation products, rain dispersion products and roofing accessories, centralized mail systems, and electronic package solutions. The Infrastructure segment provides engineered solutions for bridges, highways, and airfields including structural bearings, expansion joints, pavement seals, elastomeric concrete, and bridge cable protection systems. The Agtech segment offers growing and processing solutions including designing, engineering, manufacturing, full scope construction, and maintenance and support of greenhouses, indoor growing operations, and botanical extraction systems. The company was founded on September 1, 1972 and is headquartered in Buffalo, NY.

Gibraltar Industries Inc.

Gibraltar Strengthens Roofing Portfolio With $1.3 Billion Omnimax Acquisition

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Omnimax is expected to generate $565 million in FY2025 adjusted net sales and $110 million in adjusted EBITDA.</li><li>The purchase price is 8.4 times OmniMax’s expected 2025 EBITDA, after factoring in $35 million in planned cost savings and about $100 million in tax benefits.</li><li>ROCK stock is down 3.6% in premarket trading on Monday.</li></ul>&nbsp;Gibraltar Industries, Inc. (ROCK), on Monday, signed an agreement to acquire OmniMax International for $1.335 billion.<a href="https://stocktwits.com/symbol/ROCK">ROCK stock</a> was down 3.6% at $57 in premarket trade.<h2 class="st-heading-2">Why Did Gibraltar Acquire OmniMax?</h2>Gibraltar will acquire Omnimax from Strategic Value Partners and its affiliates, with the transaction expected to be completed in the first half of fiscal year 2026.The target company is a residential roofing accessories and rainware solutions provider that is expected to generate $565 million in adjusted net sales and $110 million in adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) in 2025. Its brands include Amerimax, Berger Building Products, Flamco, Verde, Millennium Metals, Hancock Enterprises and Nu-Ray Metals.The purchase price is 8.4 times OmniMax’s expected 2025 EBITDA, after factoring in $35 million in planned cost savings and about $100 million in tax benefits.The acquisition is expected to strengthen Gibraltar’s core residential segment, which is anticipated to represent more than 80% of revenue and adjusted EBITDA upon completion of the transaction. Gibraltar expects immediate accretion in EBITDA margin and earnings per share (EPS) in the first full fiscal year.Gibraltar secured committed financing from Bank of America, Wells Fargo, and KeyBanc Capital Markets, including up to $1.3 billion in term loans and an expanded $500 million credit line.<h2 class="st-heading-2">What Is The Retail Sentiment?</h2>Retail sentiment on Stocktwits remained in the ‘neutral’ territory over the last 24 hours. The stock has been on a downtrend lately, declining in 11 of the previous 13 sessions.The stock has a short interest of 2.2% according to Koyfin data.ROCK shares have seen a marginal 0.6% decline year-to-date.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/arm-holdings-draws-investor-interest-as-stock-continues-to-hover-near-200-dma-after-4-consecutive-sessions-of-decline/cLPkvLvREIU">Arm Holdings Draws Investor Interest As Stock Continues To Hover Near 200-DMA After 4 Consecutive Sessions Of Decline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

Gibraltar will acquire Omnimax from Strategic Value Partners and its affiliates, with the transaction expected to be completed in the first half of fiscal year 2026.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$40.10
Prev Close	$40.33
Open	$39.91
Dividend Yield	0.00%
50-Day Moving Average	$41.60
Beta	1.31
Avg. Volume	361,900.01
PE Ratio	-7.91

52-Week High	$63.59
52-Week Low	$33.56
Market Capitalization	$1.19B
EPS (Annual)	-$1.49
Price to Book	1.34
Revenue Per Employee	$493,696.09

Feed

News

Sentiment

Earnings

Fundamentals

Info

ROCK Fundamentals